Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the DESTINY-Breast04 trial data, but adding the DESTINY-Breast06 data to the label ...

She is fundraising to access a targeted cancer drug called Enhertu, which is not widely available on the NHS for women with her type and stage of cancer. Without NHS funding, it can cost over £ ...

3 Days of Design 2025: live updates from the Wallpaper* team From 18-20 June, design is taking over Copenhagen. Follow along with the latest news, launches and other goings-on from 3 Days of Design, ...

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.